Skip to main content
Skip to navigation
Research Exchange
Living Lab
Discovery Lab
Donate
Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in
HRR
‐mutated, platinum‐resistant ovarian cancer: A substudy of
KGOG
3045”
· 2023-10-31
1
Citations
Links
DOI
PubMed
Journal
International Journal of Cancer